Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Last year, DNAPrint successfully completed a similar project with Pharsight corporation (Nasdaq:PHST) 2001
The agreement expands to 18 the list of FDA-approved drugs for which DNAPrint is now developing pharmacogenomics classifiers, or chemopredictive tests.
SARASOTA, Fla.--(BUSINESS WIRE)--May 7, 2002--DNAPrint genomics, Inc. (OTCBB:DNAP) announced today that it has teamed with Altura, LLC of Aliso Viejo, CA to expand its research and product development efforts to address a number of undisclosed prescription drugs.
Altura will provide DNAPrint with clinically phenotyped samples for an undisclosed class of drugs, and DNAPrint will use the samples for population genomics research aimed at developing chemopredictive tests for an individualization of therapy. Drugs of the class targeted by the agreement exhibit markedly variable response rates and adverse events in the patient population. Because of this, a significant number of patients are exposed to unnecessary health risks for long periods of "treatment" time until the right drug and/or dose is found through trial and error. Due to the size of the market for the class of drugs, the agreement could have substantial implications for the company's quest to grow long-term earnings potential.
The agreement will compliment DNAPrint's current collection efforts, and enhance DNAPrint's multi-drug consent databank by 500 patients over the course of 2002. Last year, DNAPrint successfully completed a similar project with Pharsight corporation (Nasdaq:PHST), but DNAPrint continues to collect most of its specimens using its own private network of Florida physicians. The agreement expands to 18 the list of FDA-approved drugs for which DNAPrint is now developing pharmacogenomics classifiers, or chemopredictive tests.
With this agreement, DNAPrint gains access to Altura's expertise, which include project planning, implementation, obtaining IRB approval and collecting qualified specimens and relevant clinical data from patients throughout the US who are taking selected medications. Due to their large number of clinical relationships and knowledge of organized health systems, Altura is particularly adept at collecting data and enrolling large number of patients and physicians in an efficient manner. Terms of the agreement remain undisclosed.
DNA Print Pharmaceuticals Inc......Here's a little something from the second quarter report/2002
http://www.sec.gov/Archives/edgar/data/1127354/000107087602000071/alturaserviceagmt.htm
11. Communications And Payments
11.1 Checks shall be made payable to: "Altura" and sent to:
Altura, LLC
20 Bronco St.
Trabuco Canyon, CA 92679
Attention: Pete Fronte
11.2 Any notice required or permitted hereunder shall be in writing and shall be deemed given as of the date it is:
(a) delivered by hand;
(b) received or refused by Registered or Certified Mail, postage prepaid, return receipt requested; or
(c) received by facsimile, as can be presumptively demonstrated by return fax or letter demonstrating successful facsimile transmission; and addressed to the party to receive such notice at the address (es) and/or facsimile telephone number(s) set forth below, or such other address as is subsequently specified to the notifying party by the receiving party in writing.
6
If to Altura, notice should be sent to:
Altura
Attention: Pete Fronte
20 Bronco St.
Trabuco Canyon, CA 92679
Telephone Number: 949-858-3947
Facsimile Number: 949-858-3161
If to DNA Print, notice should be sent to:
DNA Print Pharmaceuticals Inc.
900 Cocoanut Ave.
Sarasota, Florida 34236
Attention: Tony Frudakis, Ph.D.
Altura's web site:
http://www.altura2000.com/articles.html
FOR IMMEDIATE RELEASE
DNAPrint Partners with Altura to Expand Research and Product Development
Investor Contact
Carrie Castillo (941) 366-3400
Sarasota, FL - March 6, 2002 - DNAPrint genomics, Inc. (OTCBB: DNAP) announced today that it has teamed with Altura, LLC of Aliso Viejo, CA to expand its research and product development efforts to address a number of undisclosed prescription drugs.
Altura will provide DNAPrint with clinically phenotyped samples for an undisclosed class of drugs, and DNAPrint will use the samples for population genomics research aimed at developing chemopredictive tests for an individualization of therapy. Drugs of the class targeted by the agreement exhibit markedly variable response rates and adverse events in the patient population. Because of this, a significant number of patients are exposed to unnecessary health risks for long periods of "treatment" time until the right drug and/or dose is found through trial and error. Due to the size of the market for the class of drugs, the agreement could have substantial implications for the company's quest to grow long-term earnings potential.
The agreement will compliment DNAPrint's current collection efforts, and enhance DNAPrint's multi-drug consent databank by 500 patients over the course of 2002. Last year, DNAPrint successfully completed a similar project with Pharsight corporation (NASD:PHST), but DNAPrint continues to collect most of its specimens using its own private network of Florida physicians. The agreement expands to 18 the list of FDA-approved drugs for which DNAPrint is now developing pharmacogenomics classifiers, or chemopredictive tests.
With this agreement, DNAPrint gains access to Altura's expertise which include project planning, implementation, obtaining IRB approval and collecting qualified specimens and relevant clinical data from patients throughout the US who are taking selected medications. Due to their large number of clinical relationships and knowledge of organized health systems including managed care, Altura is particularly adept at collecting data and enrolling large number of patients and physicians in an efficient manner. Terms of the agreement remain undisclosed.
Ramipril, an ACE inhibitor used widely for years for high blood pressure or heart disease, appears to be the first drug ever to prevent diabetes. In a large study just published, Ramipril reduced the rate of diabetes by 30% in patients participating in research because of their high risk for heart disease. It was also found to reduce the risk of death from heart disease by 20% as well as death rates from stroke by 30%.
Fosinopril is used to treat high blood pressure and heart failure. It decreases certain chemicals that tighten the blood vessels, so blood flows more smoothly and the heart can pump blood more efficiently.
This medication is sometimes prescribed for other uses; ask your doctor or pharmacist for more information.
Enalapril is used to treat high blood pressure and heart failure. It decreases certain chemicals that tighten the blood vessels, so blood flows more smoothly and the heart can pump blood more efficiently.
MANUFACTURER: Pfizer, Accupril TABLETS CAN be split in half. This medicine is an ACE inhibitor used to treat high blood pressure. It may also be used to treat congestive heart disease and other conditions as determined by your doctor
This has got to be Big in Tonys game plan started over a year ago.
b) Facilitate the collection of the following per the study synopsis:- Up to 500 DNA samples (via swabs) of patients on the following Ace Inhibitors:Lisinipril, Quinapril, Enalapril, Benzapryl, Fosinopril and Ramapril- required bioinformation and clinical data on up to 500 patients that have provided DNA (specifics TBD)
ifida, Nice work, I dont know how it got by me.That whole filing is in my mine a Licenseing agreement and looks like its in phase 3 trial with 500 patients. Check out the drugs Dnap is using under this agreement:
b) Facilitate the collection of the following per the study synopsis: - Up to 500 DNA samples (via swabs) of patients on the following Ace Inhibitors:[bLisinipril,Quinapril,Enalapril, Benzapryl, Fosinopril and Ramapril - required bioinformation and clinical data on up to 500 patients that have
provided DNA (specifics TBD)
This was all set to go back in April 15,2002. Trials could be done and FDA approval next in line.WOW I need to look into this a lot more. Thanks Again for brings this to light.
Right now we are spending most of our efforts working on solving problems associated with other people's drugs such as Lipitor or Bristol-Myer's Taxol drug. In the not so distant future, we are going to have our own drug pipeline and we will apply our talents toward solving our drugs rather than other people's drugs.
novicetx, you must be a Big teddy Bear ! Cause with posts like that you must be getting a lot of Hugs. To Da moooooooooooooooonnnnnnnnnnnnnnn $$$$$$$$$
bag8ger,Thanks again for your precocious view on this. There are so many different directions one can go with it, your support in this matter is very helpful to me and my family.
I was going a little in both directions;
1} In Dnap considering acquiring a small drug comp.
2}The making of their own drug.
Hector Gomez is a strong and compelling force for Dnap. I know he is on the board of directors of many different comp. {Phase 5 Sciences,PRB Pharmaceuticals,Clinication,Zengen,Saneron,Semaphore and a partner w/ Genbiomics} to name just a few.And Luchese with BIG GOV. We seem to have a chess game going on with all major peices. There are many Latent possibilitys and all very Tenable.
Theo,I have to agree with Quintessential nature of your post,partner/merger or other business arragement sounds more likely. On the other hand shtuff does happen and we could have a new drug comp. Thanks again for you very analytical synopsis.
bag8ger, Thanks! What's your take on the following ?
"This does not account for deals that help us become a pharmaceutical company, and if we acquire a pipeline with advanced candidates, both drug development expenses and winfall from a drug approval would significantly change these numbers".
This to happen within a Year ? If so there's more going on at Dnap than we know. Got to go back to work ,will read your responce later. Later
All Read this Dnap making its own Drug !!!!
"This does not account for deals that help us become a pharmaceutical company, and if we acquire a pipeline with advanced candidates, both drug development expenses and winfall from a drug approval would significantly change these numbers".
CEO of DNAprint genomics predicts revenues to grow over next 24 months
Tony Frudakis, DNAprint genomics, Inc.
TONY FRUDAKIS is Chief Scientific Officer, Board member and Head of Research of DNAprint genomics, Inc.
For Subscribers
Get the complete article now!
Eight analysts and top management from twenty seven sector firms examine the Biotechnology sector in this 149-page Biotechnology Issue from The Wall Street Transcript, available at (212/952-7433) or www.twst.com
TWST: Could you start us off with a brief summary of DNAprint genomics?
Dr. Frudakis: DNAprint genomics is a small genomics firm that is focused on extracting value from the human genome sequence. That is clinical value, forensics value and recreational value. So we have made great progress in the forensics space and you may have heard about that through the media surrounding the Louisiana serial killer case which we helped break with genomics tests we have developed here. But our main purpose is to determine why people respond to drugs differently so that the response can be predicted beforehand. Right now we are spending most of our efforts working on solving problems associated with other people's drugs such as Lipitor or Bristol-Myer's Taxol drug. In the not so distant future, we are going to have our own drug pipeline and we will apply our talents toward solving our drugs rather than other people's drugs. But what really sets DNAprint apart from other genomics companies is that we think we are the only ones who know how to accurately determine what it is that makes people respond to drugs differently. The reason why is that we are the only company that appreciates the fact that something called population structure can be used as a tool to hone in on genomic sequences that can be used to predict response. So basically our advantage is a scientific and technical one. We do things better than even the large pharmaceutical companies do because we were comprised of young, very bright scientists who think innovation, not old school. Our founding group was comprised of a group of scientists and not a group of business people and we got the business expertise after the fact.
TWST: What should the next 24 months hold as far as DNAprint being a success?
Dr. Frudakis: Revenues will continue to grow. We will begin to make more of an impact on serial murder and serial killer cases in the forensics space. We will be putting together partnerships with other companies to help us realize the power of our forensics program. The most important thing of all is that people will begin to see the step we are taking to become a new type of pharmaceutical company ' the one that makes the laser-guided weapons and not the dumb-bombs. By the end of two years, I hope it will be clear to everyone that we are that type of company. We are not just a test company but a pharmaceutical company.
TWST: What are the overriding principles of the rate of spend you are going to have to put out versus what you see as revenue and the need for capital?
Dr. Frudakis: I can give you some projections. We think that total stockholders equity which is projected to be at $160,000 in 2004 will grow to $700,000 in 2005 and $12 million in 2006 based on our forensics business and our physical profiling, mainly the Taxol test I told you about. Property and equipment is going to grow as well. We have about $2 million worth of scientific equipment right now and that is going to grow to about $6 million in the next couple of years. Right now, every time we issue shares to raise funding, it counts as negative cash. Even though we have $200,000 in the bank and that amount stays pretty much constant because as it is spent, more is added in, if you look on the books, there is negative cash in the bank. That is because we have issued stock to pay for it. That will stay negative until 2006 when we think we will have about $8 million in cash. We project $60 million by 2007 based on all of the things happening that we talked about ' DNAprint's forensics' business continuing the growth it has, recreational business continuing the growth it has. This does not account for deals that help us become a pharmaceutical company, and if we acquire a pipeline with advanced candidates, both drug development expenses and winfall from a drug approval would significantly change these numbers.
This special issue includes:
1) Biotechnology - In an in-depth (9,700 words) Roundtable Forum, Jennifer M. Chao, a Senior Analyst & Managing Director at RBC Capital Markets, Michael G. King, a Managing Director & Senior Equity Research Analyst at Banc of America Securities, Eric Schmidt, a Managing Director and Senior Research Analyst at SG Cowen Securities Corp. and Thomas Shrader, a Research Analyst at Harris Nesbitt Gerard, Inc., examine the outlook for the sector and share specific stock recommendations.
2) Small Cap Biotechnology Companies - In an in-depth (3,500 words) Analyst Interview, Russell Gilbertson, a Research Analyst at Roth Capital Partners, LLC, examines the outlook for the sector and shares specific stock recommendations.
3) Biotechnology, Genomics & Gene Therapy - In an in-depth (4,300 words) Analyst Interview, Craig D. West, an Associate Vice President and Senior Biotech Analyst at A.G. Edwards & Sons, examines the outlook for the sector and shares specific stock recommendations.
4) Investing in Biotechnology - In an in-depth (1,700 words) Analyst Interview, Rahul Jasuja, a Research Analyst at Techvest, LLC, examines the outlook for the sector and shares specific stock recommendations.
5) Therapeutics-Based Companies - In an in-depth (3,600 words) Analyst Interview, Mark Schoenebaum, a principal & Senior Research Analyst at U.S. Bancorp Piper Jaffray Inc., examines the outlook for the sector and shares specific stock recommendations.
6) CEO interviews (average 2,500 words). Top management of twenty seven - sector firms examine the outlook for their firm and the sector.
Dnaprint.New case.
http://newsobserver.com/front/story/2742087p-2541956c.html
Friday, August 1, 2003 12:00AM EDT
Police enlisting DNA tool
Technology being used in Bennett investigation
By OREN DORELL, Staff Writer
RALEIGH -- Police trying to find Stephanie Renee Bennett's killer are enlisting a crime-fighting tool that is on the cutting edge of science -- technology that can identify a suspect's race from a speck of DNA left at the scene.
The technique is likely to become more powerful, as geneticists learn to identify eye and hair color, height and possibly other physical characteristics from the chemical code that is embedded in human cells and defines who we are.
No one has been arrested in Bennett's rape and murder at a North Raleigh apartment complex May 21, 2002.
Investigators are releasing possible behavioral traits and other information to the public in hopes of triggering tips about possible suspects. On Tuesday, they said they believe the killer is in his 20s or early 30s and might have a military background. Investigators admit that one or more traits could be wrong.
But in addition to the killer's sex, the one characteristic they are sure of is his race -- white, with 92 percent of Indo-European heritage and 8 percent Native American, to be exact.
Investigators used the new DNA technique to break the serial killer case in Louisiana earlier this year. Profilers predicted that the suspect would be white and police had collected more than 1,000 DNA samples, mostly from white men. But after DNA identified the killer as black, police redirected their investigation. They requested a sample from Derrick Todd Lee, who left town after submitting a DNA sample. He was eventually arrested and charged with five slayings.
Raleigh investigators have obtained voluntary DNA samples from friends, neighbors and colleagues of Bennett but don't plan any dragnets seeking hundreds of samples just based on race or other physical traits.
Lt. Chris Morgan, who is leading the Bennett investigation, has said that anyone who refused a request for a DNA sample would invite more scrutiny from investigators.
But police stress that DNA profiling technology is so new that it can only be used as an investigative tool -- they are not even sure they could use it to obtain a search warrant.
The forensic test for race, which retails for $1,000 and is called DNA Witness, uses 71 DNA markers called "snips" (for single nucleotide polymorphisms). About 3 million snips make up each person's genome, though not all carry information, said Zach Gaskin, technical director of forensic genomics at DNAPrint, the Sarasota, Fla., company that developed the test.
The test identifies what percentage of the donor's ancestry is sub-Saharan African, East Asian, Native American and Indo-European.
"The major percentage corresponds nearly perfectly to what the person would self- report," Gaskin said. "It's a valuable forensic tool, because it would give you a general sense of the person's racial or ancestral background."
A civilian form of the test is available to the public for $158. Raleigh police took advantage of a $360 introductory offer before the Louisiana case made DNAPrint famous.
To help clients with such broad race categories, the company plans to provide law enforcement clients with 20 to 25 photographs of people with similar ancestral histories as their suspect, Gaskin said.
And the technology has more to offer, said Mark Shriver, assistant professor of anthropology and genetics at Pennsylvania State University and a consultant to DNAPrint.
"From studies that we've done already, we know that we are going to be able to predict pretty well skin color, eye color, hair color, hair texture, extremes of height, extremely short and tall," he said.
The current eye- color test, which could be available to the public later this year, categorizes the donor's eyes as either dark, which includes brown and dark brown, or light, which includes blue, green and hazel colored eyes, Shriver said. The company may develop a photographic chart for eye color similar to the one for race, he said.
Raleigh police Capt. Don Overman said that when the new tests are available, investigators intend to use them to glean more information about Bennett's killer.
Some warn that such a powerful tool carries risks depending on what happens when someone refuses to provide a voluntary DNA sample.
"It would be a really bad thing for law enforcement in particular and society in general to equate someone's insistence on a right to privacy with guilt," said Raleigh defense attorney Karl E. Knudsen.
But he also said the new technology could help the innocent.
"As a tool, it can just as often eliminate someone as a possible suspect as include them," Knudsen said.
By: mjam3
31 Jul 2003, 11:31 PM EDT
Msg. 266205 of 266251
(This msg. is a reply to 266202 by Gcbr.)
Jump to msg. #
Arch - I took pretty detailed notes on his presentation. I'll post more tomorrow. My fingers are cramping now. But I will share one quick excerpt. Tony was closing his soft sell with an analogy about his dad. When Tony was in graduate school George was a victim of a carjacking and fought back. He was shot in the face. The assailant's driver's license miraculously fell out during the crime. The police found it and tracked down the guy and arrested him. Tony's close was that his toolkit would eventually do the same thing i.e. provide the same information found on a driver's license about a criminal leaving DNA at a scene.
Advertisements
By: mjam3
31 Jul 2003, 10:58 PM EDT
Msg. 266191 of 266251
(This msg. is a reply to 266174 by vrholdings.)
Jump to msg. #
vrh - in regards to 144s - I made an offhand comment about how we all watched with great interest any 144s related to Tony, his family and related parties. Tony said he regularly files and does required business with his shares regardless of share price and at regular intervals. Very similar response to what someone posted within the last week about a practice most companies now have in place due to insider selling investigations related to the Martha Stewart case. I would put very little "stock" into the 144 filings.
IMO shares have been and will continue to be sold to guarantee day to day continuity.
We asked Tony if we had any problems identifying potential investors and he said none whatsoever. The hard times are over IMO.
By: mjam3
31 Jul 2003, 11:08 PM EDT
Msg. 266197 of 266251
(This msg. is a reply to 266177 by bulldogsbite.)
Jump to msg. #
bulldog - I counted about 125 people in attendance, all forensics folks from TX and around the country. The mix was about 50/50 male / female. Tony was introduced as the founder of the company they had all been hearing so much about in the news lately.
- - - - -
By: mjam3
31 Jul 2003, 10:51 PM EDT
Msg. 266185 of 266251
(This msg. is a reply to 266171 by ice105.)
Jump to msg. #
Ice, et al. - Tony presented a pretty dry analysis of how he (and Mark Shriver) developed the science and technology leading up to the tools 1) Iris - Retinome, 2) Hair - Retinome HA, 3) skin tone and 4) admixture - DNAWitness. He then led in to a close which was a soft sell of the product line up. He gave some specifics on how the LA serial case unfolded. Some questions at the end on price, size of sample, etc... Absolutely nothing new to this board other than the enhanced versions of the test for forensics using the 71 AIM, 175 AIM and 1000 AIM tests. He did say that we were running the most advanced tests in the world and many of DNAPs experiments were first time ever type events.
He was above the head of the audience with the science but he had to lay out the process to validate the tools. When I commented on this he alluded to it being the same way with big pharma. When he meets with them the science is way over their heads. He said it was 10 times easier to develop the science to predict drug response that to predict the forensics tools.
Tony also confirmed what a few of us have been saying for almost a year. Forensics and Ovanome and Statnome are merely tools to provide "proof of principle", i.e. the science works. These are not the means to the end. What we (at least I) didn't know was that becoming a drug company was the end game. A simple plan.
By: novicetx
31 Jul 2003, 09:53 PM EDT
Msg. 266156 of 266251
(This msg. is a reply to 266147 by stockholder101.)
Jump to msg. #
Just wait and see. When asked about working with a certain company (which will go nameless here,) he said maybe we would do something with them down the road, but that for now "We have bigger fish to fry."
I read people pretty well, and I got the feeling that Tony is as genuine as they come. He exudes confidence in the company's future. I also had the sense that his plan for the company is as brilliant as his science. Hector and Richard are there for their networking capabilities.
I wish every stockholder had had the opportunity to listen to him, as we did. I'm not spending another minute trying to second guess him--or responding to those who do.
He just said to be patient, and we'd be glad we were.
Just got in. Tony is phenomenal. He said to be patient. The company has a modified vision that he has authorized us to report as a general statement.
We will become a drug company in a short time frame (within a year is a good estimate).
Tony sat with me radean, novicetx and grateful for a good 30 minutes. He was totally engaged with us, very forthright and totally confident in the future. The hard days are behind us. Many small companies in similar positions to ours have gone under. There is no chance of that with us.
I can give more information later but I have to run again. There is good news on the forensics front as this was the focus of the presentation to this particular audience.
We have news coming in the near future. He told us it would be dangerous to us as individuals to speculate about that news in this forum due to SEC scrutiny and crackdown. Therefore I will not do it.
He also said to tell of you longs thanks for sticking in there, be patient and the payoff will be there; both financially and for the good of humanity.
I'll be back later. mjam
AAFDA Conference By greatful101
It looks like a couple of the others from the conference have already posted and I agree with their assessment, but want to add a few comments of my own.
Tony is well spoken and comes across as brilliant yet humble. I walked away feeling more confident than ever about my investment. For those of you who want specific details, here are a few of the things I can remember:
Ancestry - there are two new versions of the tests available now. One uses 175 markers rather than the 71 used in the original test, the other uses 1000. The more markers used the greater the accuracy, but 71 markers are sufficiently accurate for the forensic version of the test. The tests they are doing are as advanced as any in the world. Some are first time ever type tests. Tony also mentioned that forensic testing was never intended to be their main line of business it is more of an offshoot of the work they are for drug response and disease susceptibility.
Retinome - they are redoing the some of the Retinome tests. The original tests were based on self-reported eye-color and were not accurate enough. Commercial tests for eye-color and hair color are expected later this year. Also, available later this year will be an expanded version of Ancestry that provides a further breakdown of the four groups that current version of the test provides.
Statnome - is at approximately the same stage in development as Ovanome. Both are in clinical trials, and we should be hearing more about the progress of both soon.
One final comment, I regret speculating this morning that there may be something in the works between Affymetrix and DNAPrint. Nothing I heard this afternoon supported my assumption. Time will tell.
Gcbr,
Yes I agree arch, did you ever wonder if Dr. S will ever end up working at Dnap as a full time employee ? I'm sure there's more money in it for him.
Aerobleu,You know the conference is on Thur., and some how I get this feeling that Tony has been advised "behind closed doors" that there will be some very Big and important people there to ask him some very direct questions that could lead to a BIG money making deal, so he's bring along Dr. mark Shriver. I mean Tony can handle it alone SO WHY bring his generals to, get it.I think this is good, great even.And something Big Can come of it. What do you think ?
Aerobleu, ok no problem. Hope you find what your looking for.
Aerobleu, its post2095 from Ming. a few posts down your joking right. LOL
On Matthew J. Thomas - The company is also pleased to announce that Matthew J. Thomas, Ph.D. will be joining the company as a Scientist from his post at the H. Lee Moffit Cancer Center, University of South Florida, Tampa, FL. Dr. Thomas obtained his Ph.D. in Biology from the Department of Biology and Institute of Molecular Biology, University of Oregon. He is the recipient of the competitive Leukemia Society of America Fellowship, and has published original molecular biology research in such prestigious journals as Cell, Oncogene, Gene and Nucleic Acids Research. The addition of Dr. Thomas will help increase the Companies data flow and analysis."
From the Leukemia and Lymphoma Society 2001 Annual Report: Research Grant recipient Matthew J.Thomas, PhD –1999 University of South Florida.
Yiwen He, Michael K Armanious, Matthew J Thomas & W Douglas Cress. Identification of E2F-3B, an alternative form of E2F-3 lacking a conserved N-terminal region. Oncogene 13 July 2000, Volume 19, Number 30.
Matthew J. Thomas, Angelina A. Platas, and Diane K. Hawley. Transcriptional Fidelity and Proofreading by RNA Polymerase II. Cell May 15, 1998: 93 (4).
Matthew J. Thomas, Edward Seto. Unlocking the mechanisms of transcription factor YY1: are chromatin modifying enzymes the key? Gene Volume 236, Issue 2, Page 197-355 (20 August 1999).
Dnap will be Cash Flow Neutral in second Qt. Yes you heard it first here on "INVESTORSHUB" yes REVENUES,BIG MONEY, PROFIT and everyone's favorite "lucrative" and lets not forget the old one BUT Good one "the MONEY MAKER" LOL
Looks like Gabriel and Tamborini were in fact together previously. It was mentioned that they came from the same place and WOW I think that is true!! I guess it must be if they have a daughter name Nicci. Someone needs an ancestry test here. All kidding aside this seems like a good move...keep the family (Pharma eco) together.
http://www.nicciandpaul.com/parents.html
This link will give some of the deep thinkers something ponder over. Explain it to me if you can.
Keiden, nice find !!! Husband and wife team ok she can keep a eye on him.LOL
Who is David A. Kalow you should know he's in Dnap 10k filing:
David A. Kalow, Kalow & Springut. David has litigated major biotechnology patent cases involving oligonucleotide synthesis and genetic antisense. He has published and lectured on bioinformatics, gene patenting, and the benefits of intellectual property audits. David focuses on litigating, licensing and protecting intellectual property of biotechnology, chemical, computer, electronics and Internet companies and the counseling of clients regarding efficient strategies for intellectual property protection, business planning and transactional matters. For many years, David has been a guest lecturer on Intellectual Property Law for the Seton Hall University Law School Sports Symposium.
Pharm-Eco Laboratories, Inc.
25 Patton Road
Devens, MA 01432
Phone: (978) 772-1644
Web site: www.pharmeco.com
Revenues: Approximately $22 million in 1999.
Key Personnel: David Wade, president and chief executive officer; Monica Tamborini, chief financial officer; Richard Gabriel, executive vice president, new ventures; Salah Zahr, Ph.D., executive vice president, scientific affairs; Lee Piver, vice president, marketing and business development; Robert Bondaryk, Ph.D., vice president, corporate development; Dick Einig, Ph.D., director of the quality unit; Tom Saulnier, senior director of engineering; Emile Bellott, Ph.D., director of medi-cinal chemistry; Adel Moussa, Ph.D., assistant director of medi-cinal chemistry; Yesh Sachdeva, Ph.D., director of government contracts and new products; Emile Al-Farhan, Ph.D., senior director of chemical development; Heather Taft, Ph.D., director of chemical development, laboratory operations
Capabilities/Capacities: PharmaSuite is Pharm-Eco’s suite of capabilities, expertise, services, technologies, scientists and chemists and customer-focused alliances. PharmaSuite provides outsourcing for discovery, process R&D and related support services. The company offers a wide array of value-added pharmaceutical services, including API Development, cGMP-compliant manufacturing, analytical services, discovery/medicinal/ combinatorial chemistry services, stability management under ICH guidelines and regulatory services.
Comments: Pharm-Eco re-cently moved into a new 20-acre world-class campus. The new location provides 160,000+ square feet, with capacity for 450+ professionals in three buildings. Pharm-Eco will expand from its 22 state-of-the-art, cGMP-compliant laboratories for API synthesis, re-search and development, to more than 50 labs during the next year. In the long-term, Pharm-Eco plans to expand the Devens campus to 60 acres during the next five years to provide one-stop shopping for API and drug product development and manufacturing. The company also plans to build eight reactor suites within a new cGMP-compliant Pilot Plant, housing up to 500 gallon glass-lined reactors.
In August, 1998, Pharm-Eco formed Universal Pharma Technologies (UPT), a joint venture with UOP. UPT offers a technology portfolio centered on its Simulated Moving Bed (SMB) technology, which provides pharma clients with an advanced tool for accelerating drug development with synthesis/separation process solutions.
How else do you pay someone $120,000 and give the Pr. Dept. a major change over. He came into a great deal of money.Way to go Tony keep Banging away at it, you doing ok by me.
Dnap will be Cash Flow Neutral in second Qt. Yes you heard it first here on "INVESTORSHUB" yes REVENUES,BIG MONEY, PROFIT and everyone's favorite "lucrative" and lets not forget the old one BUT Good one "the MONEY MAKER" LOL